NASDAQ:TVGN

Tevogen Bio Holdings Stock News

Healthcare > Biotechnology

Buy TVGN

*Your capital is at risk

$9.06

+0.590 (+6.97%)

At Close: Jun 03, 2026

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

05:34pm, Friday, 24'th Jan 2025

WARREN, N.J., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shel

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

07:53pm, Thursday, 23'rd Jan 2025

WARREN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shel

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

12:21pm, Thursday, 26'th Dec 2024

WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Con

Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference

09:38am, Monday, 23'rd Dec 2024

WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

08:30am, Thursday, 19'th Dec 2024

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf

Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound

02:29am, Wednesday, 18'th Dec 2024

Initiated a small position in Tevogen Bio Holdings Inc. due to a promising pipeline and favorable seasonal patterns, despite only one Wall Street analyst covering it. Tevogen Bio develops T-cell thera

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

01:32pm, Tuesday, 17'th Dec 2024

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

03:13pm, Tuesday, 10'th Dec 2024

WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

11:03am, Thursday, 05'th Dec 2024

WARREN, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, CEO of Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech d

Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy

08:05am, Tuesday, 26'th Nov 2024

WARREN, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

03:59pm, Thursday, 21'st Nov 2024

WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

04:50pm, Tuesday, 19'th Nov 2024

WARREN, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

05:00pm, Thursday, 14'th Nov 2024

Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm. Tevogen's success would no

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

03:49pm, Thursday, 14'th Nov 2024

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

03:36pm, Friday, 08'th Nov 2024

WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by